CTOs on the Move

VAYA Pharma

www.vayapharma.com

 
At VAYA Pharma, we are committed to improving quality of life and delivering products that exemplify our key values. VAYA Pharma`s history of clinical research is based on understanding the potential of the human body in order to reform medicine. Through this research, we have discovered a strong correlation between certain disorders and lipid imbalances in affected individuals. Because of this, VAYA Pharma focuses on developing innovations for the clinical dietary management of disorders that are specifically associated with lipid imbalances. Our products deliver a nutritional based solution that are familiar to the human body and clinically proven to be ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.vayapharma.com
  • 800 West Baltimore Street Ste. 100
    Baltimore, MD USA 21201
  • Phone: 410.297.0020

Executives

Name Title Contact Details

Similar Companies

Advanced Environmental Testing And Abatement

Advanced Environmental Testing And Abatement is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Casa Assisted Living

La Casa Assisted Living is a Merritt Island, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verseon

Verseon is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.